Junshi Biosciences collaborates with Coherus Biosciences to co-develop anti-PD-1 antibody and grants options for anti-TIGIT and IL-2 cytokine molecules
Clients Shanghai Junshi Biosciences Co., Ltd.
Jones Day represented Junshi Biosciences in its license out of technology and IP related to an anti-PD-1 antibody known as Toripalimab and options for two other molecules. Junshi will transition many ongoing clinical trials in the USA for Toripalimab to Coherus, who will undertake further development and regulatory activities after transition and exclusive commercialization of all resulting approved products in the USA and Canada. Junshi receives $150 million upfront and has the potential of receiving $1.11 billion in milestone payments plus royalties. Junshi also granted to Coherus options for an anti-TIGIT antibody and a next generation IL-2 cytokine.